CriticalFirst-generation antipsychotic, diphenylbutylpiperidine derivative×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
Voriconazole is a strong CYP3A4 inhibitor and itself a QT prolonger. Double torsades risk. FDA Orap Section 4.
Symptoms
QTc above 500 ms by day 2–3, syncope, torsades de pointes.
Management
Combination contraindicated. For invasive mycosis in a pimozide patient, hold pimozide during the voriconazole course and resume 7 days after.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Pimozide tablet (Par Health USA, LLC) – Prescribing Information (2011)– FDA Orap label, Section 4 Contraindications; DailyMed setid 70b079e2-a1f7-4a93-8685-d60a4d7c1280
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3